ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 0880

Investigating the SRPK-1-VEGF-A Alternative Splicing Pathway AsaTherapeutic Target in Arthritis

Cytokines & Cell Trafficking Poster

10:30AM-12:30PM: Abstract Number: 1463

Investigation of the Cardiometabolic-related Mechanism of Action of Apremilast Through Plasma Proteomics Profiling of Patients with Psoriasis or Psoriatic Arthritis from Three Phase 3 Studies

SpA Including PsA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 0945

Involvement of Cellular Senescence in Rheumatoid Arthritis-associated Interstitial Lung Disease of SKG Mice

Rheumatoid Arthritis – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 0932

IRAK4 Degrader GS-6791 Inhibits TLR and IL-1R-Driven Inflammatory Signaling, and Ameliorates Disease in a Preclinical Arthritis Model

Innate Immunity Poster

10:30AM-12:30PM: Abstract Number: 1615

Is Regular Vascular Imaging Scheduled Essential in the Follow-Up of Takayasu Arteritis? A Large-Scale Multicenter Cohort Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1446

Is the Remission Achieved with Asdas, Basdaı a Real Remission? Should Ultrasound Be Added to the Parameters?

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 0916

Isocitrate Dehydrogenase 2 Mutations Are Associated with Autoimmune Rheumatologic Diseases in Chronic Myelomonocytic Leukemia

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 1164

IVIG Treatment Duration in Immune-mediated Necrotizing Myopathy and a Possible Association of Vacuolar Changes with Black/African American Female Patients

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1117

JAK Inhibitor Therapy in Refractory Uveitis Due to Immune-mediated Inflammatory Disorders. Multicenter Study and Literature Review

Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1357

Kidney Function in Rheumatoid Arthritis: Estimating Glomerular Filtration Rate Using Creatinine versus Cystatin C in a Secondary Analysis of the TARGET Trial

RA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1552

Kinetics of Mucocutaneous and Musculoskeletal Responses to Deucravacitinibin Patients with Active SLE in the Phase 2 PAISLEY Trial

SLE – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1303

Knee Injection Training for Internal Medicine Residents in Real-world Primary Care Practice

Professional Education Poster

10:30AM-12:30PM: Abstract Number: 1222

Large Language Model-driven Sentiment Analysis for Facilitating Fibromyalgia Diagnosis

Pain in Rheumatic Disease Including Fibromyalgia Poster

10:30AM-12:30PM: Abstract Number: 0983

Life Satisfaction in Adults Living with Arthritis – a Cross-Sectional Analysis of the 2022 National Health Interview Survey

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 0971

Ligand-Receptor Analysis Reveals Myeloid-Mediated Pro-Inflammatory Responses and Loss of Mesenchymal Signaling Driven by TNFR1 in Experimental Pulmonary Hypertension

Systemic Sclerosis & Related Disorders – Basic Science Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].